Back HCV Prevention Injection Drug Use

HIV and Hepatitis C Risk Factors and Prevention Among People Who Inject Drugs

More than half of young injection drug users in the U.S. shared syringes previously used by others and a large majority reported unprotected sex, according to the latest data on people who inject drugs from the National HIV Behavioral Surveillance System, published in the July 4 edition of Morbidity and Mortality Weekly Report Surveillance Summaries. The survey found that 9% had HIV and 41% had hepatitis C.

alt

Read more:

Health and Human Rights Advocates Call for Repeal of Syringe Funding Ban

More than 140 organizations involved in HIV and viral hepatitis advocacy, public health, harm reduction, and human rights sent an open letter last week calling on legislators to lift the federal ban on funding for needle and syringe exchange programs intended to curb the transmission of blood-borne diseases among people who inject drugs.

alt

Read more:

CROI 2014: Monkey Studies Confirm Validity of Injectable PrEP

Two studies in monkeys of an injectable formulation of the third-generation integrase inhibitor drug GSK1265744 (or GSK744LA, where LA stands for "long-acting") have strengthened the evidence that it may work as pre-exposure prophylaxis (PrEP) in humans, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. A Phase 2 study in humans will be starting soon.

alt

Read more:

EASL 2014: Treatment as Prevention for Drug Users Could Slash HCV Prevalence

A combination of increased testing, improved linkage to care, and earlier treatment with interferon-free regimens has the potential to substantially reduce the incidence and prevalence of hepatitis C among people who inject drugs in France over the next 10 years, as well as reducing the burden of disease arising from cirrhosis over 40 years, according to a study presented at the 49th EASL International Liver Congress (EASL 2014) last week in London.

alt

Read more:

CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]

A long-acting injectable formulation of the next-generation integrase inhibitor GSK1265744 protected monkeys from infection via vaginal or anal exposure to a hybrid human-simian virus, according to 2 studies presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These promising findings suggest this may be a future approach to pre-exposure prophylaxis (PrEP).

alt

Read more: